{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:49:38Z","timestamp":1782103778037,"version":"3.54.5"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD4 T-cell responses are important for the protection conferred by many infectious disease vaccines and can be quantitatively and qualitatively improved by adjuvants. The AS01 adjuvant is present in critical licensed or candidate vaccines against, amongst others, zoster, respiratory syncytial virus, malaria and tuberculosis. During their clinical development, these vaccines have been evaluated in populations ranging from immunologically na\u00efve to strongly pathogen-primed individuals. We dissected the vaccine-induced CD4 T-cell responses across these studies, to elucidate how pre-existing immune memory in the host drives the polyfunctional phenotype of the vaccine-induced CD4 T cells. Across the investigated vaccines, a consistent pattern emerged, in which the capacity of antigen-specific vaccine-induced CD4 T cells to produce interferon-\u03b3 appeared to depend on increased levels of prior exposure, leading to pre-existing memory T cells. As the dominant origin of a vaccine-induced CD4 T-cell response (i.e., memory cells with a pre-existing T-cell receptor repertoire, or newly recruited na\u00efve cells) remains to be clarified, this observation helps to guide future research into efficacious next-generation vaccines tailored to the specific immune priming status of the target population.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1800411","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:35:54Z","timestamp":1782102954000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CD4 T cell phenotype after AS01-adjuvanted immunization is shaped by prior antigen or pathogen exposure"],"prefix":"10.3389","volume":"17","author":[{"given":"Robbert G.","family":"van der Most","sequence":"first","affiliation":[{"name":"VaxxCellence","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[{"name":"Center for Vaccinology (CEVAC), Ghent University and Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: A decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01262","article-title":"Polyfunctional CD4+ T cells as targets for tuberculosis vaccination","volume":"8","author":"Lewinsohn","year":"2017","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci175378","article-title":"Advances in understanding the mechanism of action of adult vaccines","volume":"133","author":"Cunningham","year":"2023","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128714","article-title":"Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection","volume":"10","author":"Boyd","year":"2015","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: Implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101431","article-title":"Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis","volume":"50","author":"Scriba","year":"2020","journal-title":"Semin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: From mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8618","article-title":"Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature","volume":"12","author":"De Mot","year":"2020","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412732","article-title":"An innate immune signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time","volume":"15","author":"Tasdighian","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl3381","article-title":"Functional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine","volume":"16","author":"Bechtold","year":"2024","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.08.035","article-title":"Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq160","article-title":"An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers","volume":"52","author":"Van Braeckel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.16744","article-title":"Respiratory syncytial virus vaccination in adult allogeneic hematopoietic cell transplant recipients","volume":"334","author":"L\u00f6tscher","year":"2025","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf626","article-title":"Impaired cellular immune responses to herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","volume":"65","author":"Kallmark","year":"2025","journal-title":"Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1953346","article-title":"Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: Polyfunctional immune responses and lessons for clinical practice","volume":"17","author":"Stadtmauer","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16534","article-title":"Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients","volume":"21","author":"Hirzel","year":"2021","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70152","article-title":"New insights into factors shaping CMV-specific T-cell polyfunctionality after hematopoietic cell transplantation","volume":"101","author":"Sadowska-Klasa","year":"2026","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.03.017","article-title":"Influence of immune aging on vaccine responses","volume":"145","author":"Gustafson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343454","article-title":"Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function","volume":"43","author":"Dintwe","year":"2013","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276505","article-title":"Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses","volume":"17","author":"Coccia","year":"2022","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1183727","article-title":"Polyfunctional antibodies: A path towards precision vaccines for vulnerable populations","volume":"14","author":"Purcell","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41577-021-00554-7","article-title":"Modulation of immune responses to vaccination by the microbiota: Implications and potential mechanisms","volume":"22","author":"Lynn","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.582201","article-title":"The role of systems vaccinology in understanding the immune defects to vaccination in solid organ transplant recipients","volume":"11","author":"Scanlon","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41467-025-57562-7","article-title":"Longitudinal single cell profiling of epitope specific memory CD4+ T cell responses to recombinant zoster vaccine","volume":"16","author":"Wen","year":"2025","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci172634","article-title":"Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity","volume":"133","author":"Laing","year":"2023","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112940","article-title":"Whole blood can be used as an alternative to isolated peripheral blood mononuclear cells to measure in vitro specific T-cell responses in human samples","volume":"492","author":"Moris","year":"2021","journal-title":"J Immunol Methods"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/21645515.2017.1381809","article-title":"Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine","volume":"14","author":"Moris","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: A randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1164\/rccm.201208-1385oc","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults","volume":"188","author":"Day","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7554\/elife.51889","article-title":"A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses","volume":"9","author":"Pallikkuth","year":"2020","journal-title":"Elife"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/nejmoa1208394","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105335","article-title":"The inactivated herpes zoster vaccine HZ\/su induces a varicella zoster virus specific cellular and humoral immune response in patients on dialysis","volume":"108","author":"Hielscher","year":"2024","journal-title":"EBioMedicine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41541-024-01004-w","article-title":"Immune correlates of protection as a game changer in tuberculosis vaccine development","volume":"9","author":"Wang","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4161\/hv.8570","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02A: Tolerability and immunogenicity in humans","volume":"5","author":"Von Eschen","year":"2009","journal-title":"Hum Vaccin"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00133-10","article-title":"Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F\/AS02A candidate tuberculosis vaccine in purified protein derivative-negative adults","volume":"17","author":"Leroux-Roels","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00564","article-title":"Adjuvant-associated peripheral blood mRNA profiles and kinetics induced by the adjuvanted recombinant protein candidate tuberculosis vaccine M72\/AS01 in Bacillus Calmette-Guerin-vaccinated adults","volume":"9","author":"van den Berg","year":"2018","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2012.10.011","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD positive adults: A randomized controlled phase I\/II study","volume":"93","author":"Spertini","year":"2013","journal-title":"Tuberculosis (Edinb)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000000343","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I\/II, randomized trial","volume":"28","author":"Thacher","year":"2014","journal-title":"AIDS"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9949-3","article-title":"A randomized, controlled dose-finding phase II study of the M72\/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults","volume":"33","author":"Montoya","year":"2013","journal-title":"J ClinImmunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000002459","article-title":"A randomized, controlled safety, and immunogenicity trial of the M72\/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults","volume":"95","author":"Kumarasamy","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013120","article-title":"Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial","volume":"97","author":"Kumarasamy","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B55","unstructured":"Incidence of tuberculosis (per 100,000 people)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102710","article-title":"Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S\/AS01 malaria vaccine","volume":"188","author":"Horowitz","year":"2012","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(25)00124-9","article-title":"Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial","volume":"12","author":"Dagnew","year":"2025","journal-title":"Lancet HIV"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Idoko","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070690","article-title":"Progress and recent developments in HIV vaccine research","volume":"13","author":"Shim","year":"2025","journal-title":"Vaccines"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.07.050","article-title":"Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers","volume":"25","author":"Goepfert","year":"2007","journal-title":"Vaccine"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e3182373b77","article-title":"Induction of strong HIV-1\u2013specific CD4+ T-cell responses using an HIV-1 gp120\/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1\u2013infected individuals","volume":"59","author":"Lichterfeld","year":"2012","journal-title":"JAIDS J Acquired Immune Deficiency Syndromes"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.043","article-title":"The F4\/AS01B HIV-1 vaccine candidate is safe and immunogenic, but does not show viral efficacy in antiretroviral therapy-naive, HIV-1-infected adults: a randomized controlled trial","volume":"95","author":"Dinges","year":"2016","journal-title":"Medicine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.058","article-title":"Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat\/AS01B vaccination","volume":"38","author":"Van Der Meeren","year":"2020","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00617-13","article-title":"Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine","volume":"21","author":"Leroux-Roels","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.030","article-title":"Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study","volume":"32","author":"Harrer","year":"2014","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9490-6","article-title":"Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine","volume":"31","author":"Van Braeckel","year":"2013","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12916-022-02536-5","article-title":"The duration of protection against clinical malaria provided by the combination of seasonal RTS,S\/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone","volume":"20","author":"Cairns","year":"2022","journal-title":"BMC Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025786","article-title":"Circumsporozoite-specific T cell responses in children vaccinated with RTS,S\/AS01E and protection against P falciparum clinical malaria","volume":"6","author":"Olotu","year":"2011","journal-title":"PLoS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621489114","article-title":"Systems analysis of protective immune responses to RTS,S malaria vaccination in humans","volume":"114","author":"Kazmin","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1\/2 randomized clinical trial","volume":"227","author":"Leroux-Roels","year":"2023","journal-title":"J Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-425","article-title":"Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older","volume":"14","author":"Couch","year":"2014","journal-title":"BMC Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.182618999","article-title":"STAT4 serine phosphorylation is critical for IL-12-induced IFN-\u03b3 production but not for cell proliferation","volume":"99","author":"Morinobu","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.01.015","article-title":"The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-\u03b3 locus","volume":"152","author":"Gomez","year":"2013","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41541-023-00613-1","article-title":"Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design","volume":"8","author":"Loos","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B75","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41541-021-00337-0","article-title":"Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants","volume":"6","author":"Budroni","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41541-026-01402-2","article-title":"Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity","volume":"11","author":"Paila","year":"2026","journal-title":"NPJ Vaccines"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:36:01Z","timestamp":1782102961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2026.1800411"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1800411","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1800411"}}